Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Van Enkel Biotechnology

Request full access

Developing novel anti-cancer drugs targeting signaling pathways

ChinaFounded 2019Biotech & Life Sciences

About Beijing Van Enkel Biotechnology

Beijing Van Enkel Biotechnology, also known as FindCure Biosciences, is a clinical-stage biopharmaceutical company founded in 2019. The firm is dedicated to the research and development of innovative anti-cancer drugs, concentrating on targeting signaling pathways and immunotherapy. Its pipeline includes small molecule targeted drugs as well as macromolecular proteins and antibody drugs, all protected by independent intellectual property rights.

The company operates from the Beijing Economic and Technological Development Zone and has a presence in Zhongshan, Guangdong. In recent years, FindCure has secured significant funding to advance its clinical programs. A notable Series A funding round, which raised tens of millions of yuan, was supported by a consortium of investors including Hecheng Capital, Huaying Health, Renxi Fund, Yishang Huicheng, and Dilianxing. This followed earlier investments from Share Capital and South China Venture Capital.

FindCure aims to develop first-in-class or best-in-class drugs with the potential for breakthrough performance in the global market. The company actively participates in the scientific community, hosting forums on the application of nuclear medicine in oncology and achieving recognition in national innovation and entrepreneurship competitions.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Drug Development, Pharmaceutical, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Feb 2026 $28M $110M Hecheng Capital · Renxi Fund · Zhongzhi Pharmaceutical Group ↗
SERIES A✓Equity / VC Sep 2023 $2.8M $11M Huaying Health Fund · Hecheng Capital · Renxi Fund · Beijing Yishang Huicheng ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Van Enkel Biotechnology website traffic

Latest recorded traffic for Beijing Van Enkel Biotechnology is 170 monthly website visits.

Latest monthly visits170
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Van Enkel Biotechnology in its local ecosystem

Live from Dealroom

The Beijing Van Enkel Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Huaying Health Fund
  • Hecheng Capital
  • Renxi Fund
  • Beijing Yishang Huicheng
  • Dilianxing
  • Zhongzhi Pharmaceutical Group
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Van Enkel Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Van Enkel Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.